1.
Journal of Clinical Hepatology
; (12): 1402-1405, 2022.
Article
de Chinois
| WPRIM
| ID: wpr-924722
RÉSUMÉ
Nonalcoholic steatohepatitis (NASH) is a liver disease with a relatively high prevalence worldwide and greatly threatens human health. In recent years, farnesoid X receptor-related drugs have played an important role in regulating the metabolism of bile acid, glucose, and lipids and inhibiting inflammation. This article summarizes the application of farnesoid X receptor agonists in the treatment of NASH, so as to provide a basis for the prevention and treatment of NASH.